YH23537 + Celecoxib + YH23537 placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Knee Osteoarthritis

Conditions

Knee Osteoarthritis

Trial Timeline

May 2, 2016 → Sep 26, 2017

NCT ID

NCT02759198

About YH23537 + Celecoxib + YH23537 placebo

YH23537 + Celecoxib + YH23537 placebo is a phase 2 stage product being developed by Yuhan for Knee Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02759198. Target conditions include Knee Osteoarthritis.

What happened to similar drugs?

11 of 20 similar drugs in Knee Osteoarthritis were approved

Approved (11) Terminated (0) Active (9)

✅NISEDr. Reddy's LaboratoriesApproved

✅Capsaicin Topical SolutionAstellas PharmaApproved

✅ImrecoxibJiangsu Hengrui MedicineApproved

✅celecoxibPfizerApproved

✅Ibuprofen + Placebo + CelecoxibPfizerApproved

✅Celecoxib + Naproxen + PlaceboPfizerApproved

✅Celecoxib + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02759198	Phase 2	Completed	May 2, 2016	Sep 26, 2017	Knee Osteoarthritis

Competing Products

20 competing products in Knee Osteoarthritis

See all competitors

Product	Company	Stage	Hype Score
NISE	Dr. Reddy's Laboratories	Approved	40
NISELAT	Dr. Reddy's Laboratories	Pre-clinical	23
LY2828360 + Placebo	Eli Lilly	Phase 2	35
UBX0101 or placebo	Unity Biotechnology	Pre-clinical	8
UBX0101	Unity Biotechnology	Phase 1	19
UBX0101	Unity Biotechnology	Phase 2	25
UBX0101	Unity Biotechnology	Phase 1	19
YM150 + Warfarin	Astellas Pharma	Phase 2	35
ASP7962 + Naproxen + Placebo	Astellas Pharma	Phase 2	35
Capsaicin Topical Solution	Astellas Pharma	Approved	43
CGS-200-1 + CGS-200-5 + CGS-200 Vehicle	Astellas Pharma	Phase 2	35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo	Sun Pharmaceutical	Phase 2	35
Duloxetine + Placebo	Shionogi	Phase 3	40
Duloxetine	Shionogi	Phase 3	40
V120083 + Naproxen + Placebo	Shionogi	Phase 2	35
ONO-4474 + Placebo matching ONO-4474	Ono Pharmaceutical	Phase 2	27
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine (DLX) + Placebo (PLA)	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40
Placebo + LY545694 49 mg + LY545694 105 mg	Eli Lilly	Phase 2	35